中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

12 records (took 0.012 seconds)

    PD-1-based vaccines against coronavirus infection
    4.
    发明授权
    PD-1-based vaccines against coronavirus infection 有权

    公开(公告)号：US12018063B2

    公开(公告)日：2024-06-25

    申请号：US17186822

    申请日：2021-02-26

    Applicant: Versitech Limited

    Inventor： Zhiwei Chen ,  Kwok Yung Yuen ,  Honglin Chen ,  Yik Chun Wong ,  Li Liu

    IPC: C07K14/705 ,  A61K39/12 ,  A61P31/14 ,  C07K14/165

    CPC classification number: C07K14/70521 ,  C07K14/165 ,  C07K2319/30

    Abstract: Disclosed soluble PD-1 (sPD-1) proteins and nucleic acids, and therapeutic compositions comprising sPD-1 proteins and nucleic acids, for enhancing immunity of a subject against coronavirus infection. Disclosed are soluble PD-1 fusion proteins that include a soluble PD-1 protein fragment and an antigenic protein fragment, preferably where the antigenic protein fragment comprises a coronavirus protein fragment. In some forms, the coronavirus protein fragment is derived from a coronavirus receptor binding domain (RBD) or a coronavirus nucleoprotein (N). In some forms, the sPD-1 proteins, nucleic acids, and compositions are formulated as a vaccine composition. Also disclosed are methods for treating a subject at risk of or suffering a coronavirus infection.

    Live attenuated influenza B virus compositions methods of making and using thereof
    6.
    发明授权
    Live attenuated influenza B virus compositions methods of making and using thereof 有权

    公开(公告)号：US12156910B2

    公开(公告)日：2024-12-03

    申请号：US17294603

    申请日：2018-11-16

    Applicant: Versitech Limited

    Inventor： Honglin Chen ,  Pui Wang ,  Kwok Yung Yuen

    IPC: A61K39/145 ,  A61P31/16 ,  A61K39/00

    Abstract: The NS1 protein of influenza virus is a key virulent element with multi-functional roles in virus replication and acts as a strong interferon (IFN) antagonist. A live attenuated virus (LAIV) is provided using a master backbone, which contains the influenza B (HK8038) virus and includes a deletion of the NSI coding region (DelNS1). The LAIV is based on novel adaptive mutations, which support DelNS1 influenza B live attenuated virus (LAIV) replication in vaccine producing cells. DelNS1 influenza B LAIV shows spontaneous cold adaption with preference to grow at 30-33° C. but restriction at 37-39° C. The LAIV can be used to protect a subject, against a lethal challenge of antigenic distant influenza B viruses. DelNS1 LAIV with adaptive mutations for growing in vaccine producing systems is an important strategy for making highly attenuated and immunogenic live attenuated influenza vaccines with the ability to induce broad cross protective immunity for seasonal influenza.

    ALVEOLAR ORGANOIDS, METHODS OF MAKING AND USES THEREOF
    8.
    发明申请
    ALVEOLAR ORGANOIDS, METHODS OF MAKING AND USES THEREOF 有权

    公开(公告)号：US20250123274A1

    公开(公告)日：2025-04-17

    申请号：US18688178

    申请日：2022-08-25

    Applicant: Versitech Limited ,  Centre for Virology, Vaccinology and Therapeutics Limited

    Inventor： Jie Zhou ,  Man Chun Chiu ,  Cun Li ,  Kwok Yung Yuen

    IPC: G01N33/50 ,  C12N5/071

    Abstract: Methods for obtaining a population of differentiated alveolar cells, differentiated alveolar cells in the form of alveolar organoids generated by the methods and uses for the differentiated alveolar organoids are provided. The methods include digesting long-term expanding lung organoids (LO) into single cells (i.e., dissociated cells), and suspension culturing the dissociated cells in distal differentiation (DD) cell culture media in a non-adherent plate for an effective amount of time. Alveolar organoids includes a population of AT1 and AT2 cells and in suspension culture exhibit an apical-out polarity and include abundant cytoplasmic lamellar bodies and microvilli. The alveolar organoids can be utilized alone or in combination with 2D and 3D AWO, rebuilt the human respiratory epithelium in culture plates for studying biology and pathology of human respiratory system, including, but not limited to, the study of COVID-19 respiratory diseases.

Patent Agency Ranking